Feedback
We would very much appreciate any thoughts you may have about OpenCME and how it could be made more useful for physicians like you.
Memorial Sloan-Kettering Cancer Center
New York, New York
| Credit Types: | CME |
| Credit Amount: | 0.5 Credits |
| Release Date: | 2011-Jun-09 |
| Expiration Date: | 2012-Jun-08 |
| Estimated Time for Completion: | 30 minutes |
| Registration Required: | No |
| Cost: | Free |
This activity provides an update of recent clinical trial findings in the areas of renal cell and urothelial carcinoma based on data reported at the 2011 Genitourinary Cancers Symposium. In addition, expert perspectives on the clinical and research implications of the study findings are presented.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of genitourinary malignancies.
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: June 09, 2011 - June 08, 2012
Time to Complete: 30 minutes
In accordance with ACCME requirements, the University of Florida College of Medicine, has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Robert J. Motzer, MD
Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York
Robert J. Motzer, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Genentech, Inc.
Grant/Research Support from GlaxoSmithKline; Novartis Oncology; and Pfizer Inc.
Zev Wajsman, MD, FACS, FRCS (C)
Professor Emeritus and Adjunct Professor
Department of Urology
University of Florida
Gainesville, Florida
Zev Wajsman, MD, FACS, FRCS (C), currently has no financial interests/relationships or affiliations in relation to this activity.
Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education
Kadrin Wilfong, MD, currently has no financial interests/relationships or affiliations in relation to this activity.
Sabby Muneer, PhD
PVI, PeerView Institute for Medical Education
Sabby Muneer, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Florida College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This CME activity is jointly sponsored by the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from Genentech, Inc.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
"OpenCME has initially been made available in a "beta" edition with minimal content, functionality and online presence. Our editorial team is working hard to add many other specialty areas to the list above."
Patient with metastatic RCC has progressed on 1st-line treatment with sunitinib. What 2nd-line option would you recommend for best outcome?
Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.
Please use the form below if you would like to offer your website visitors high quality CME content by adding the OpenCME Widget to one or more of your pages.